Pfizer Inc.: Drug Recall
Recall #D-0102-2024 · 10/02/2023
Class I: Dangerous
Recall Details
- Recall Number
- D-0102-2024
- Classification
- Class I
- Product Type
- Drug
- Recalling Firm
- Pfizer Inc.
- Status
- Terminated
- Date Initiated
- 10/02/2023
- Location
- New York, NY, United States
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 3,200 vials
Reason for Recall
Presence of Particulate Matter: identified as glass.
Product Description
2% Lidocaine HCl Injection, USP, 100mg/5mL(20mg/mL), Glass ABBOJECT Unit of Use Syringe, packaged as 1 vial and injector per carton, Rx only, Distributed by Hospira Inc., Lake Forest, IL 60045, NDC 0409-4903-11
Distribution Pattern
Nationwide in the US and Puerto Rico. The products were not distributed to government accounts or foreign consignees.
Other Recalls by Pfizer Inc.
- Class II: Risk 08/04/2025
- Class II: Risk 08/04/2025
- Class II: Risk 07/10/2025
- Class II: Risk 07/10/2025
- Class II: Risk 05/28/2025
Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.